Roger N. Hayes, Ph.D., has been appointed president of Bioanalytical Operations at Cetero Research. Dr. Hayes has more than 15 years of scientific experience and leadership in bioanalytical testing, pharmacokinetics and pharmacodynamics, as well as extensive expertise in drug metabolism, high-throughput drug discovery and drug development. He will be based in Cetero’s bioanalytical lab in Houston, TX.

Dr. Hayes joins the company from Schering-Plough Research Institute, part of Merck Research Laboratories, where he served as director of bioanalytical for the last 10 years. He has also held positions with Parke-Davis Pharmaceuticals, now a division of Pfizer, Procter & Gamble, and the University of Nebraska-Lincoln.

“We are honored to have such an accomplished scientist and business leader join us. Cetero is committed to bringing innovation to drug development, and his appointment is one additional step in allowing us to accomplish that goal. Roger has in-depth experience developing bioanalytical methods using mass spectrometry, chromatography and automation, which will allow us to enhance our analytical service offerings to our clients,” said Troy W. McCall, Ph.D., Cetero’s chief executive officer. “In addition, Roger’s vast knowledge of the entire drug development process will help us develop more innovative and effective solutions to help our clients improve efficiencies in their development processes.”